CNC

Over the past six months, Centene's stock experienced several notable events and trends. In February 2026, Centene reported its Q4 2025 and full year 2025 earnings, with a GAAP diluted loss per share of $(13.53) for the full year 2025 and an adjusted diluted EPS of $2.08. Remarks by CEO Sarah London at the Barclays 28th Annual Global Healthcare Conference in March 2026 led to a significant drop in Centene's share price due to concerns about potential losses in ACA membership. In April 2026, Centene reported strong first-quarter 2026 results, with EPS and revenues exceeding analyst expectations, and increased its 2026 GAAP Diluted EPS Guidance to greater than $2.37. Centene's stock experienced a significant reduction in share price in the past year, reaching a low of around $25 in August 2025, before rising to around $47 in January 2026, and as of May 8, 2026, the stock price was $55.96.